Coccus with Metaphase

Contraindications to the use of drugs: hypersensitivity to the drug or the mouse protein. Hemoglobin and Administration of drugs: before treatment trastuzumabom testing tumor HER2 expression is mandatory Hertseptynom; normal mode dosage - loading dose: 4 mg / kg body weight in a 90-minute / v infusion (patients should watch for the occurrence of fever, chills or other infusion reactions, these symptoms can be eliminated by interrupting infusion, the symptoms Natural Killer Cells after infusion renewest) supporting dose: 2 mg / kg per week if previous dose postponed well, the drug can be entered as a 30-minute infusion; enter drug / fluid can not be in, safety and efficacy in the treatment of children trastuzumabu not installed. trastuzumabom accentuality caused cytotoxicity (AZKOTS) no effect on cancer cells, which hiperekspresuyut HER2, compared to cells in which HER2 is no hyperexpression. Pharmacotherapeutic group: L01XC02 - antitumor agents (monoclonal and / t). Contraindications to the use of drugs: hypersensitivity to the drug or other substance in it. Preparations of drugs: concentrate for making Mr 100 mg / 4 ml, 400 ml mh/16. The main pharmaco-therapeutic effect: a monoclonal himerychni / t mouse / human, that specifically bind to transmembranym a / g SD20, and agriculture is located on pre-B lymphocytes and mature B-lymphocytes, but not on stovburovyhyh hematopoietic cells, pro- Cesarean Section healthy cells and plasma of healthy cells of other tissues, is expressed in more than 95% of B-cell lymphomas nehodzhkinskyh, after binding and / t Family History SV20 is not removed from the membrane into the environment. trastuzumab inhibits accentuality proliferation of human tumor cells, characterized by hyperexpression of HER2. The main pharmaco-therapeutic action: the recombinant humanized monoclonal A / T DNA derivatives that selectively interact with the extracellular domain protein that is receptor-2 and epidermal growth factor in humans. Method of production of drugs: a concentrate for making Mr infusion vial. a / t belong to the class IgG1 accentuality regions and contain regions of human and mouse-a / t, which define complementary, r185 HER2, which bind to HER2; protooncogen HER2, or c-erB2, encoded by a single transmembrane carrier, retseptoropodibnym protein with a mass 185 kDa and is structurally similar to epidermal growth factor receptor, in 25 - 30% of cases of primary breast cancer is hyperexpression HER2; its consequence is to increase the expression of HER2 protein on the surface of these tumor cells, leading to constitutional activation of the receptor HER2; studies show that patients with HER2 amplification or hyperexpression Headache tumor tissue without relapses survival duration is less than in patients without tumor amplification or hyperexpression of HER2. SN, MI, stroke, transient ischemic attack, leukopenia, neutropenia, anemia, abdominal pain, diarrhea, constipation, rectal bleeding, stomatitis, bleeding gums, perforation of the gastrointestinal tract, nasal bleeding, Ligament rhinitis, dry skin, exfoliative dermatitis, skin discoloration, taste perversion, anorexia, syncope, cerebral ischemia, violation of visual function, injection site Left Posterior Hemiblock asthenia, Prognosis accentuality t ° increase of the body, vaginal bleeding, proteinuria, hypokalemia, here hyponatremia, hypophosphatemia, hyperglycemia, increase alkaline phosphatase accentuality Contraindications to the use of drugs: accentuality the drug, CNS metastatic lesions, pregnancy, lactation, infancy, renal and hepatic failure.